Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer: results from the european prospective investigation into cancer and nutrition study
Molecular Epidemiology Research Group, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Hum-boldt-Universität zu Berlin, Berlin, Germany.
Molecular Epidemiology Research Group, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Department of Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology—BIPS, Bremen, Germany; Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany.
Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC-WHO), World Health Organization, Lyon, France.
Show others and affiliations
2024 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 154, no 9, p. 1596-1606Article in journal (Refereed) Published
Abstract [en]

Resistin is a protein involved in inflammation and angiogenesis processes and may play a role in the progression of colorectal cancer (CRC). However, it remains unclear whether resistin is associated with increased mortality after CRC diagnosis. We examined pre-diagnostic serum resistin concentrations in relation to CRC-specific and all-cause mortality among 1343 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. For CRC-specific mortality as the primary outcome, hazard ratios (HRs) and 95% confidence intervals (95% CI) were estimated from competing risk analyses based on cause-specific Cox proportional hazards models and further in sensitivity analyses using Fine–Gray proportional subdistribution hazards models. For all-cause mortality as the secondary outcome, Cox proportional hazards models were used. Subgroup analyses were performed by sex, tumor subsite, tumor stage, body mass index and time to CRC diagnosis. Resistin was measured on a median of 4.8 years before CRC diagnosis. During a median follow-up of 8.2 years, 474 deaths from CRC and 147 deaths from other causes were observed. Resistin concentrations were not associated with CRC-specific mortality (HRQ4vsQ1 = 0.95, 95% CI: 0.73–1.23; Ptrend =.97; and HRper doubling of resistin concentration = 1.00; 95% CI: 0.84–1.19; P =.98) or all-cause mortality. Results from competing risk (sensitivity) analysis were similar. No associations were found in any subgroup analyses. These findings suggest no association between pre-diagnostic circulating resistin concentrations and CRC-specific or all-cause mortality among persons with CRC, and the potential insignificance of resistin in CRC progression.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024. Vol. 154, no 9, p. 1596-1606
Keywords [en]
colorectal cancer, EPIC, mortality, pre-diagnostic, resistin, survival
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-219757DOI: 10.1002/ijc.34830ISI: 001139607900001PubMedID: 38200695Scopus ID: 2-s2.0-85181970494OAI: oai:DiVA.org:umu-219757DiVA, id: diva2:1829256
Funder
World Cancer Research Fund InternationalNordForskSwedish Cancer SocietySwedish Research CouncilRegion SkåneRegion VästerbottenAvailable from: 2024-01-18 Created: 2024-01-18 Last updated: 2024-05-07Bibliographically approved

Open Access in DiVA

fulltext(1307 kB)110 downloads
File information
File name FULLTEXT02.pdfFile size 1307 kBChecksum SHA-512
7c05c62b86638e9e48f56358ace684ccfc6b556c95f5af7ce3387461b8d460008b6c8e53ae59f9a4756162b5e18f2b13b781a387f1630c8e76fbddcc3dcf3ee1
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Lu, Sai San Moon

Search in DiVA

By author/editor
Lu, Sai San Moon
By organisation
Oncology
In the same journal
International Journal of Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 146 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 306 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf